Twist Bioscience (NASDAQ:TWST) CFO Sells $93,450.00 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 3,000 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, October 8th. The shares were sold at an average price of $31.15, for a total value of $93,450.00. Following the sale, the chief financial officer directly owned 94,042 shares in the company, valued at $2,929,408.30. This trade represents a 3.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Adam Laponis also recently made the following trade(s):

• On Thursday, October 9th, Adam Laponis sold 2,517 shares of Twist Bioscience stock. The stock was sold at an average price of $32.92, for a total value of $82,859.64.
• On Monday, October 6th, Adam Laponis sold 5,875 shares of Twist Bioscience stock. The shares were sold at an average price of $32.19, for a total value of $189,116.25.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $31.19 on Monday. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -21.51 and a beta of 2.38. The firm’s fifty day moving average is $27.63 and its 200 day moving average is $32.53. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 52-week low of $24.07 and a 52-week high of $55.33.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The business had revenue of $96.06 million during the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TWST. Evercore ISI reduced their price target on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a report on Tuesday, October 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, October 8th. Barclays lowered their target price on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, October 2nd. Finally, Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $48.50.

Institutional Trading of Twist Bioscience

Several institutional investors and hedge funds have recently made changes to their positions in the company. Osaic Holdings Inc. raised its holdings in shares of Twist Bioscience by 31.6% in the second quarter. Osaic Holdings Inc. now owns 7,054 shares of the company’s stock valued at $261,000 after acquiring an additional 1,694 shares in the last quarter. Squarepoint Ops LLC increased its position in Twist Bioscience by 192.8% during the 2nd quarter. Squarepoint Ops LLC now owns 71,708 shares of the company’s stock valued at $2,638,000 after purchasing an additional 47,221 shares during the period. Geneos Wealth Management Inc. bought a new position in shares of Twist Bioscience during the second quarter valued at approximately $97,000. Soleus Capital Management L.P. bought a new position in shares of Twist Bioscience during the second quarter valued at approximately $13,038,000. Finally, Man Group plc boosted its stake in shares of Twist Bioscience by 5.3% during the second quarter. Man Group plc now owns 106,509 shares of the company’s stock valued at $3,918,000 after purchasing an additional 5,348 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.